Key Financials Snapshot

TTM · Consolidated · ₹ in Cr
Market Cap
₹35587 Cr.
Stock P/E
43.9
P/B
7.5
Current Price
₹1741.4
Book Value
₹ 232.3
Face Value
10
52W High
₹2094.3
52W Low
₹ 1564.3
Dividend Yield
0.26%

Narayana Hrudayalay. Overview

Business

Narayana Hrudayalaya Ltd. (NH) is one of India's leading multi-specialty healthcare providers, operating a chain of hospitals, heart centers, and primary care facilities. The company's core business model revolves around providing comprehensive medical services across various specialties, including cardiac sciences, oncology, nephrology, neurosciences, orthopaedics, and more. NH focuses on making high-quality healthcare accessible and affordable, often through a high-volume, asset-light (in some models) and scale-driven approach. It generates revenue primarily from patient services (consultations, surgeries, diagnostics, room rentals), pharmacy sales, and other related medical services.

Revenue Mix

While specific revenue breakdowns by specialty are not always publicly disaggregated, NH operates as a multi-specialty hospital chain. Its primary revenue streams come from:

In-patient services: Major surgeries, critical care, and long-term treatments.

Out-patient services: Consultations, diagnostic tests, and minor procedures.

Pharmacy sales: Dispensing medicines within hospital premises.

Other services: Medical tourism, health check-ups, and academic programs.

The company has a strong reputation and historical strength in cardiac sciences, which remains a significant contributor, alongside other growing specialties like oncology and nephrology. Its operations are spread across various Indian cities, with a notable presence in Karnataka and other eastern/western states, and also has an international hospital in the Cayman Islands.

Industry

The Indian healthcare sector is characterized by strong growth, driven by increasing disposable incomes, rising health awareness, a growing burden of lifestyle diseases, and under-penetration of healthcare services. The industry is fragmented, with a mix of large corporate hospital chains, standalone hospitals, and government-run facilities. Narayana Hrudayalaya is positioned as a prominent corporate hospital chain, known for its ability to perform high-volume, complex procedures at relatively affordable costs. Its 'health city' model in Bangalore and focus on economies of scale differentiate it within the competitive landscape, where it competes with other large chains like Apollo Hospitals, Fortis Healthcare, Max Healthcare, and smaller regional players. NH is particularly strong in tier-1 and tier-2 cities, aiming to cater to a broad economic spectrum.

MOAT

Scale and Volume: NH's ability to handle a high volume of complex procedures, particularly in cardiac care, allows for economies of scale, operational efficiency, and potentially lower costs per procedure, which can be passed on to patients.

Brand Reputation: A strong brand built on its founder's vision (Dr. Devi Shetty) and reputation for quality and affordability in complex surgeries, especially cardiac.

Talent Pool: Attracting and retaining a large pool of skilled doctors, surgeons, and medical professionals, especially for high-end specialties.

Cost-effectiveness: Known for offering high-quality care at relatively lower prices than some peers, particularly in complex interventions, appealing to a wider segment of the population and for medical tourism.

Growth Drivers

Increasing Healthcare Spending: Rising income levels, greater health insurance penetration, and a growing awareness of health are driving demand for quality healthcare services.

Demographic Shifts: An aging population and an increasing prevalence of chronic and lifestyle diseases necessitate more healthcare interventions.

Expansion & Capacity Addition: Organic expansion through new hospitals/beds and inorganic growth via acquisitions or partnerships in underserved or high-demand regions.

Medical Tourism: India's cost-effective quality healthcare attracts international patients, a segment NH can leverage.

Digital Health & Telemedicine: Adoption of digital platforms for consultations, diagnostics, and patient management can expand reach and efficiency.

Government Initiatives: Schemes like Ayushman Bharat (PM-JAY) can increase the patient base for empaneled hospitals like NH, particularly in secondary and tertiary care.

Risks

Regulatory Risks: Changes in healthcare policies, pricing controls for drugs and medical devices, and operational guidelines can impact profitability.

Doctor and Staff Retention: Intense competition for skilled medical professionals can lead to higher staff costs or challenges in talent acquisition.

High Capital Expenditure: Establishing and expanding hospitals requires significant capital investment, leading to potential debt and longer gestation periods for new projects.

Pricing Pressure: Competition and regulatory scrutiny can put downward pressure on treatment costs and profitability.

Medical Negligence & Litigation: Risks associated with medical errors, which can lead to reputational damage and legal liabilities.

Economic Downturns: Reduced disposable incomes or slower economic growth could impact elective procedures and patient footfall.

Management & Ownership

Narayana Hrudayalaya was founded by Dr. Devi Prasad Shetty, a renowned cardiac surgeon, who serves as the Chairman and Executive Director. The promoter group holds a significant stake in the company. Dr. Shetty's vision of making high-quality healthcare accessible and affordable forms the core philosophy of the organization. The management team includes experienced professionals from the healthcare and business sectors, steering the company's operational and strategic growth. The ownership structure reflects a typical promoter-led Indian company, with institutional investors and the public holding the remaining shares.

Outlook

Narayana Hrudayalaya is well-positioned to benefit from the secular growth trends in the Indian healthcare sector. Its established brand, focus on high-volume affordable care, and strong clinical outcomes provide a solid foundation. The company's strategy of expanding its presence and diversifying its specialty mix beyond cardiac sciences should drive future revenue and profitability.

However, the company faces inherent challenges related to capital-intensive growth, intense competition, regulatory uncertainties, and the ongoing need to attract and retain top medical talent. Managing operational efficiencies and maintaining profitability amidst pricing pressures will be crucial. The ability to successfully execute expansion plans while upholding its reputation for quality and affordability will determine its sustained success.

Narayana Hrudayalay. Share Price

Live · BSE / NSE · Inception: 2000
₹ | |
Volume
Price

Key Financials — Profit & Loss

₹ in Cr · Consolidated · annual

Narayana Hrudayalay. Quarterly Results

#(Fig in Cr.) Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026
Net Sales 1246 1306 1367 1335 1475 1507 1644 2151 2594 2684
Other Income 24 23 24 18 27 24 24 23 29 35
Total Income 1270 1330 1390 1353 1502 1531 1668 2174 2623 2719
Total Expenditure 955 1004 1058 1027 1118 1170 1241 1784 2084 2214
Operating Profit 315 326 332 326 385 361 426 390 539 505
Interest 28 34 35 37 41 45 42 65 91 87
Depreciation 65 61 65 70 83 84 87 122 154 156
Exceptional Income / Expenses 0 0 0 0 -8 0 0 -51 -0 0
Profit Before Tax 222 231 232 220 253 231 297 152 294 262
Provision for Tax 34 30 33 26 57 35 37 22 64 53
Profit After Tax 188 201 199 194 196 196 260 130 230 209
Adjustments 3 1 -1 -1 1 0 -1 -3 -6 -2
Profit After Adjustments 191 201 199 193 197 197 258 127 224 207
Adjusted Earnings Per Share 9.3 9.9 9.7 9.4 9.7 9.6 12.6 6.2 11 10.1

Narayana Hrudayalay. Profit & Loss

#(Fig in Cr.) Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
Net Sales 1614 1878 2281 2861 3128 2583 3701 4525 4890 5483 7896 9073
Other Income 16 23 19 19 28 27 35 65 92 92 100 111
Total Income 1630 1902 2300 2880 3156 2611 3736 4590 4982 5575 7996 9184
Total Expenditure 1437 1649 2061 2566 2701 2394 3038 3544 3745 4190 6257 7323
Operating Profit 193 252 239 314 455 217 698 1046 1237 1385 1739 1860
Interest 33 28 55 81 94 82 76 84 112 163 266 285
Depreciation 76 80 100 137 186 184 183 210 241 278 448 519
Exceptional Income / Expenses -11 -1 1 0 -11 0 0 0 0 -8 -51 -51
Profit Before Tax 51 135 80 93 161 -56 430 752 884 936 969 1005
Provision for Tax 30 52 29 34 42 -42 88 145 98 146 158 176
Profit After Tax 21 83 51 59 119 -14 342 607 786 790 810 829
Adjustments 0 0 -0 -0 -0 -0 0 0 3 0 -5 -12
Profit After Adjustments 21 83 51 59 119 -14 342 607 789 790 806 816
Adjusted Earnings Per Share 1 4.1 2.5 2.9 5.8 -0.7 16.7 29.7 38.6 38.7 39.4 39.9

Narayana Hrudayalay. Balance Sheet

#(Fig in Cr.) Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Shareholder's Funds 876 963 1036 1081 1136 1120 1489 2131 2884 3626 4537
Minority's Interest 0 0 0 0 1 1 1 1 1 2 2
Borrowings 188 180 696 725 619 504 432 626 1195 1966 4667
Other Non-Current Liabilities 178 181 285 316 532 440 427 410 429 469 1429
Total Current Liabilities 315 323 510 510 602 703 784 988 1224 1146 1827
Total Liabilities 1556 1647 2528 2633 2889 2768 3133 4157 5732 7257 12463
Fixed Assets 1055 1082 1848 1838 2092 1961 1980 2336 2651 4266 7796
Other Non-Current Assets 216 263 200 267 211 142 240 526 1022 442 735
Total Current Assets 272 302 479 527 586 665 913 1295 2059 2502 3932
Total Assets 1556 1647 2528 2633 2889 2768 3133 4157 5732 7257 12463

Narayana Hrudayalay. Cash Flow

#(Fig in Cr.) Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Opening Cash & Cash Equivalents -53 -11 31 -5 84 92 90 149 145 242 447
Cash Flow from Operating Activities 174 219 182 279 443 304 485 1085 1067 986 1621
Cash Flow from Investing Activities -150 -146 -534 -161 -189 -113 -267 -1174 -1458 -1325 -3700
Cash Flow from Financing Activities 18 -45 315 -27 -247 -194 -159 88 488 544 2340
Net Cash Inflow / Outflow 42 28 -36 90 8 -2 59 -2 97 205 262
Closing Cash & Cash Equivalent -11 17 -5 84 92 90 149 145 242 447 761

Narayana Hrudayalay. Ratios

# Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Earnings Per Share (Rs) 1.04 4.06 2.51 2.9 5.82 -0.7 16.74 29.68 38.62 38.66 39.42
CEPS(Rs) 4.74 7.97 7.41 9.62 14.92 8.28 25.72 39.96 50.28 52.26 61.57
DPS(Rs) 0 0 0 1 1 0 1 2.5 4 4.5 4.5
Book NAV/Share(Rs) 42.7 46.67 50.02 52.78 55.42 54.64 72.69 104.26 141.1 177.44 222.02
Core EBITDA Margin(%) 10.98 12.18 9.65 10.31 13.65 7.32 17.92 21.67 23.42 23.59 20.75
EBIT Margin(%) 5.23 8.67 5.92 6.09 8.16 1.02 13.67 18.47 20.36 20.04 15.64
Pre Tax Margin(%) 3.16 7.21 3.52 3.26 5.16 -2.17 11.61 16.61 18.08 17.06 12.27
PAT Margin (%) 1.29 4.42 2.25 2.07 3.81 -0.55 9.24 13.41 16.07 14.4 10.26
Cash Profit Margin (%) 6.01 8.67 6.64 6.87 9.75 6.55 14.2 18.05 21.01 19.48 15.94
ROA(%) 1.42 5.18 2.46 2.3 4.31 -0.51 11.59 16.64 15.9 12.16 8.22
ROE(%) 2.54 9.09 5.2 5.64 10.77 -1.27 26.3 33.55 31.35 24.27 19.86
ROCE(%) 7.45 14.09 8.94 9.34 13.61 1.46 26.83 33.92 27.58 21.62 16.2
Receivable days 33.33 30 34.88 34.79 30.85 38.21 35.27 35.02 31.85 32.53 27.99
Inventory Days 11.42 9.92 10.88 10.64 8.37 7.64 5.29 5.28 6.77 7.33 6.12
Payable days 139.96 153.91 167.76 169.49 170.21 207.83 172.49 193.96 215.88 189.19 193.39
PER(x) 274.98 77.14 110.9 73.83 42.53 0 44.59 26.08 33.15 43.74 40.73
Price/Book(x) 6.69 6.72 5.57 4.05 4.46 7.43 10.27 7.42 9.07 9.53 7.23
Dividend Yield(%) 0 0 0 0.47 0.4 0 0.13 0.32 0.31 0.27 0.28
EV/Net Sales(x) 3.76 3.51 2.83 1.78 1.81 3.4 4.22 3.58 5.56 6.59 4.5
EV/Core EBITDA(x) 31.42 26.14 27.04 16.19 12.43 40.55 22.4 15.49 21.98 26.08 20.44
Net Sales Growth(%) 18.33 16.38 21.44 25.43 9.33 -17.42 43.29 22.25 8.08 12.12 44.01
EBIT Growth(%) 29.68 93.15 -17.18 24.81 46.47 -89.84 1427.48 65.19 19.15 10.37 12.35
PAT Growth(%) 251.2 298.55 -38.05 5.78 100.84 -111.67 4687.9 77.3 29.58 0.49 2.61
EPS Growth(%) 223.96 291.15 -38.17 15.23 100.98 -112.03 2491.91 77.3 30.12 0.11 1.95
Debt/Equity(x) 0.3 0.23 0.78 0.75 0.63 0.55 0.37 0.36 0.5 0.61 1.07
Current Ratio(x) 0.86 0.93 0.94 1.03 0.97 0.95 1.16 1.31 1.68 2.18 2.15
Quick Ratio(x) 0.71 0.77 0.78 0.87 0.87 0.88 1.09 1.24 1.59 2.09 2.07
Interest Cover(x) 2.53 5.91 2.47 2.16 2.72 0.32 6.65 9.94 8.92 6.73 4.64
Total Debt/Mcap(x) 0.04 0.03 0.14 0.19 0.14 0.07 0.04 0.05 0.06 0.06 0.15

Growth Rates

Compounded annual
# 1 Year 3 Year 5 Year 10 Year
Sales CAGR +44% +20% +25% +17%
Operating Profit CAGR +26% +18% +52% +25%
PAT CAGR +3% +10% — +44%
Share Price CAGR 0% +16% +28% +18%
ROE Average +20% +25% +27% +15%
ROCE Average +16% +22% +25% +16%

Narayana Hrudayalay. Shareholding Pattern

Latest · Jun 2026
100% held
Promoters 63.27 %
FII 9.4 %
DII (MF + Insurance) 9.06 %
Public (retail) 18.27 %
# Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026
Promoter 63.8563.8563.8563.8563.8563.8563.8563.2763.2763.27
FII 10.9110.019.689.449.6610.4610.4911.19.989.4
DII 9.518.237.98.698.528.097.767.919.159.06
Public 15.7317.9118.5718.0217.9717.617.917.7117.618.27
Others 0000000000
Total 100100100100100100100100100100

Narayana Hrudayalay. Peer Comparison

Hospital & Healthcare Services Edit Columns

Narayana Hrudayalay. Quarterly Price

10-year quarterly close · BSE
Show Value Show %

News & Updates

See more…

Narayana Hrudayalay. Pros & Cons

Pros

  • Company has a good return on equity (ROE) track record: 3 Years ROE 25%

Cons

  • Debtor days have increased from 189.19 to 193.39days.
  • Stock is trading at 7.5 times its book value.
Want to Start Investing in Top Unlisted Stocks?

Our experts help you choose the right stocks based on performance, risk, and growth potential.

whatsapp